| 產品名稱 | AU565 [AU-565] |
|---|---|
| 商品貨號 | B163965 |
| Organism | Homo sapiens, human |
| Tissue | mammary gland/breast; derived from metastitic site: malignant pleural effusion |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | adenocarcinoma |
| Age | 43 years |
| Gender | female |
| Ethnicity | Caucasian, White |
| Applications | The cells are useful as models of cellular growth to study the differentiation of breast cancer cells.
|
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | The AU565 cell line was derived at the Naval Biosciences Laboratory, Oakland, CA from a pleural effusion of a patient with breast carcinoma. This cell line was established from the same patient as SK-BR-3 (ATCC HTB-30). |
| Clinical Data | 43 years
Caucasian, White
female
|
| Receptor Expression | epidermal growth factor (EGF) |
| Oncogene | her2/neu + (overexpressed); her3 +; her4 +; p53 + |
| Comments | The patient, a White, Caucasian female, age 43, blood type A+, had been treated with radiation, steroids, cytoxan and 5-fluorouracil. The AU565 cell line amplifies and overexpresses the HER-2/neu oncogene; it expresses the HER-3, HER-4 and p53 oncogenes. Treating the cells with mycophenolic acid (MPA), phorbol 12-myristate 13-acetate (PMA), retinoic acid (RA) or the TA-1 monoclonal antibody to the extracellular domain of the HER-2/neu protein can induce cell differentiation. Treatment of AU565 cells with Neu differentiation factor (NDF) also induces mature phenotype, which is characterized by the morphological appearance of the cells. Untreated AU565 cells have compact nuclei with thin cytoplasm while treated cells display a morphology associated with a differentiated phenotype such as flat large nuclei surrounded by a sizable cytoplasm.
A culture submitted to the ATCC in April of 1995 was found to be contaminated with mycoplasma and progeny were cured by a 21-day treatment with BM Cycline. The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Note: Do NOT allow cells to become confluent. Subculture at 50-60% confluency. The majority of cells should be round and undifferentiated. If cells overgrow, they can be brought back to an undifferentiated condition by maintaining them under sparse conditions for a couple of passages.
Subculture Ratio: 1:4 to 1:6 Medium Renewal: Every 3 to 5 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.
|
| Cryopreservation | culture medium 95%; DMSO, 5% |
| Culture Conditions | Temperature: 37°C |
| STR Profile | Amelogenin: X CSF1PO: 12 D13S317: 11,12 D16S539: 9 D5S818: 9,12 D7S820: 9,12 THO1: 8,9 TPOX: 8,11 vWA: 17 |
| Name of Depositor | SS Bacus |
| References | Bacus SS, et al. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol. Carcinog. 3: 350-362, 1990. PubMed: 1980588 Bacus SS, et al. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res. 52: 2580-2589, 1992. PubMed: 1373672 Bacus SS, et al. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res. 53: 5251-5261, 1993. PubMed: 8106145 Wen D, et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69: 559-572, 1992. PubMed: 1349853 Bacus SS, et al. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ. 3: 401-411, 1992. PubMed: 1358180 Peles E, et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205-216, 1992. PubMed: 1348215 Lessor T, et al. Regulation of heregulin beta1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway. J. Cell. Biochem. 70: 587-595, 1998. PubMed: 9712155 Yoo JY, et al. Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines. Breast Cancer Res. Treat. 51: 71-81, 1998. PubMed: 9877030 Yoo JY, Hamburger AW. Changes in heregulin beta1 (HRGbeta1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line. Mol. Cell. Endocrinol. 138: 163-171, 1998. PubMed: 9685225 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
